posted on 2025-11-12, 07:06authored byDenis AwanyDenis Awany, Dominique T Ariefdien, Simon MendelsohnSimon Mendelsohn, Virginie RozotVirginie Rozot, Humphrey MulengaHumphrey Mulenga, Sarah Nyangu, Michele Tameris, Tumelo Moloantoa, Austin Katona, Fernanda Maruri, Firdows Noor, Ravindre Panchia, Khuthadzo Hlongwane, Kim Stanley, Yuri F. van der Heijden, Kate Hadley, Andrew Fiore-Gartland, Craig Innes, William Brumskine, Keertan Dheda, Shameem Jaumdally, Tahlia Perumal, Neil Martinson, Al LeslieAl Leslie, Bernard Fourie, Petrus FouriePetrus Fourie, Andriëtte Hiemstra, Stephanus T. Malherbe, Gerhard Walzl, Kogieleum Naidoo, Gavin Churchyard, Novel N. Chegou, Timothy R. Sterling, Mark Hatherill, Thomas J Scriba
<p dir="ltr">This dataset contains the serum protein expression data analysed for the article “Inflammatory Biomarkers of Asymptomatic and Symptomatic Tuberculosis” (doi: https://doi.org/10.1101/2025.10.26.684319). The study characterized the biology of asymptomatic tuberculosis (TB) by analyzing blood transcriptomic and proteomic data from South African cohorts. The study characterized the biology of asymptomatic tuberculosis, revealing that it shares core inflammatory features with symptomatic disease, including upregulated innate immune and inflammatory pathways. However, the identification of two distinct sub-clusters within asymptomatic individuals - differing in bacterial burden, immune response, and clinical severity - points to underlying differences in disease state. The study subsequently derived a new blood transcriptomic signature for asymptomatic TB. The work demonstrated that existing diagnostic biomarkers, developed for symptomatic TB, performed poorly in detecting asymptomatic compared to symptomatic cases, highlighting a major limitation for their use in community screening.</p><p dir="ltr">The protein data herein were measured using Bio-Plex multiplex bead arrays on the Bio-Plex platform (Bio- Rad Laboratories, CA, USA). Samples from the RePORT SA cohort were assayed using the Bio-Plex Pro Human Cytokine 27-Plex Panel and the Bio-Plex Pro Human Apolipoprotein 10-plex Assay Panel. Samples from the CORTIS-01 cohort were assayed using the Bio-Plex Pro Human Cytokine, Chemokine, and Growth Factor 48-Plex Panel.</p>
Funding
CRDF Global (University of Cape Town: G-DAA3-19-66875-1)
CRDF Global (Vanderbilt University: G-DAA9-2066870-1)
CRDF Global (Stellenbosch University: G-DAA9-20-66918-1)
CRDF Global (Wits Health Consortium: G-DAA9-2066878-1)
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
National Institute of Allergy and Infectious Diseases
To contribute to control of the global Tuberculosis (TB) epidemic by designing a clinical trial to test a Correlates of Risk-targeted screen-and-treat strategy, which will identify people at highest risk of developing TB disease and treat them, before they become ill and transmit TB to others